Top 50 Biotechnology Angel Investors (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Jonathan Milner
Angel
|
32 | United Kingdom, United States, Spain | Seed, Series A, Series B | Biotechnology, Health Care, Medical | $537k–$56M |
|
Milad Alucozai
Angel
|
23 | United States, Canada, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Medical | $110k–$55M |
|
Jeff Dean
Angel
|
16 | United States, United Kingdom, Japan | Seed, Series A, Pre-Seed | Artificial Intelligence, Information Technology, Software | $450k–$53M |
|
Jude Gomila
Angel
|
12 | United States, United Kingdom, Canada | Seed, Pre-Seed, Angel | Software, Biotechnology, Information Technology | $190k–$4.7M |
|
Paul Buchheit
Angel
|
12 | United States, Canada, India | Seed, Series A, Angel | Software, E-Commerce, Health Care | $100k–$13M |
|
Sahin Boydas
Angel
|
10 | United States, Mexico, Norway | Seed, Series A, Series B | Software, Financial Services, Information Technology | $125k–$150M |
|
Jaffray Woodriff
Angel
|
10 | United States | Seed, Series A, Angel | Software, Biotechnology, Health Care | $250k–$11M |
|
Kingsley Advani
Angel
|
9 | United States, Singapore, United Kingdom | Seed, Pre-Seed, Series A | FinTech, Biotechnology, Financial Services | $120k–$183M |
|
Farzad Nazem
Angel
|
9 | United States, Canada | Seed, Series A, Series B | Health Care, Software, Analytics | $750k–$50M |
|
bumpkins profile
Angel
|
9 | United States, Canada, India | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Robotics | $325k–$57M |
|
Jeff Hammerbacher
Angel
|
9 | United States, Germany | Seed, Series A, Angel | Software, Artificial Intelligence, Biotechnology | $330k–$25M |
|
Sam Altman
Angel
|
9 | United States, Canada, Ghana | Seed, Series A, Series B | Software, Artificial Intelligence, Internet | $1.2M–$100M |
|
Jim Mellon
Angel
|
8 | United States, United Kingdom, Israel | Series A, Seed | Biotechnology, Food and Beverage, Health Care | $536k–$46M |
|
Alice Zhang
Angel
|
8 | United States, United Kingdom | Seed, Series A, Pre-Seed | Biotechnology, Health Care, Medical | $120k–$30M |
|
Balaji Srinivasan
Angel
|
8 | United States, India, Singapore | Seed, Pre-Seed, Series A | Blockchain, Cryptocurrency, Software | $665k–$31M |
|
Wei Guo
Angel
|
7 | United States, China, Canada | Seed, Series A, Angel | Software, Artificial Intelligence, Health Care | $200k–$19M |
|
Chris Gibson
Angel
|
7 | United States, France, Switzerland | Series A, Seed | Biotechnology, Health Care, Life Science | $4.9M–$55M |
|
Stefano Bernardi
Angel
|
6 | Italy, United Kingdom, France | Seed, Pre-Seed | Software, Biotechnology, Artificial Intelligence | $100k–$45M |
|
Bradley Horowitz
Angel
|
6 | United States, United Kingdom, Germany | Seed, Series A, Series B | Software, Information Technology, Artificial Intelligence | $150k–$120M |
|
Evan Cheng
Angel
|
6 | United States, United Kingdom, Australia | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Biotechnology | $120k–$18M |
|
Nadav Rosenberg
Angel
|
6 | United Kingdom, France, Israel | Seed, Pre-Seed, Series A | Biotechnology, Artificial Intelligence, Software | $850k–$19M |
|
Tim Draper
Angel
|
6 | United States, United Kingdom, Canada | Seed, Series A, Series B | Software, FinTech, Financial Services | $400k–$50M |
|
Charlie Songhurst
Angel
|
6 | United Kingdom, United States, Germany | Seed, Pre-Seed | Software, Information Technology, Artificial Intelligence | $510k–$8M |
|
Zach Weinberg
Angel
|
6 | United States, Israel, United Kingdom | Seed, Series A, Pre-Seed | Software, Health Care, SaaS | $1.4M–$30M |
|
Cory Levy
Angel
|
6 | United States, Canada, United Kingdom | Pre-Seed, Seed, Series A | Artificial Intelligence, Software, Advertising | $200k–$72M |
|
Brian Armstrong
Angel
|
5 | United States, Brazil, Libya | Seed, Series A, Series B | Biotechnology, Payments, Financial Services | $2M–$130M |
|
John Ballantyne
Angel
|
5 | United States | Seed, Series A, Angel | Biotechnology, Health Care, Life Science | $12M–$30M |
|
Fred Ehrsam
Angel
|
5 | United States, Canada, Israel | Seed, Series A, Series C | Blockchain, Cryptocurrency, Software | $1M–$300M |
|
Mark Cuban
Angel
|
5 | United States, United Kingdom, Canada | Seed, Series A | Software, Artificial Intelligence, Blockchain | $600k–$23M |
|
Mei Z.
Angel
|
5 | United States, United Kingdom, Singapore | Seed, Pre-Seed, Series A | Artificial Intelligence, Software, Information Technology | $1M–$300M |
|
Elad Gil
Angel
|
5 | United States, United Kingdom, Israel | Seed, Series A, Series B | Software, Information Technology, Artificial Intelligence | $2M–$100M |
|
Sake Bosch
Angel
|
5 | The Netherlands, France, Israel | Seed, Series A, Series B | Software, E-Commerce, Biotechnology | $1.9M–$77M |
|
Peter Thiel
Angel
|
5 | United States, Germany, Canada | Series A, Seed, Series B | Software, FinTech, Financial Services | $900k–$105M |
|
Kevin Moore
Angel
|
5 | United States, India, Canada | Seed, Pre-Seed, Angel | Software, Health Care, E-Commerce | $120k–$5.2M |
|
Anne Wojcicki
Angel
|
5 | United States, United Kingdom, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $1M–$70M |
|
Jan Hammer
Angel
|
5 | China, United States, France | Series A, Series B, Seed | Health Care, Medical, Medical Device | $2.5M–$250M |
|
Alec Nielsen
Angel
|
5 | United States, Germany | Seed, Pre-Seed | Biotechnology, Biopharma, Medical | $3M–$16M |
|
Erik Peterson
Angel
|
5 | United States, Canada, Algeria | Seed, Equity Crowdfunding, Series A | Software, Biotechnology, SaaS | $69k–$20M |
|
Daniel Curran
Angel
|
5 | United States, Canada, Brazil | Seed, Series A, Series B | E-Commerce, Software, Internet | $600k–$50M |
|
Bhavik Bajaj
Angel
|
5 | United States, Switzerland, United Kingdom | Pre-Seed, Seed, Angel | Information Technology, Software, FinTech | $15k–$3M |
|
Candan Karabagli
Angel
|
4 | Turkey | Seed, Angel, Series A | Retail, Analytics, Biopharma | |
|
Benjamin Kong
Angel
|
4 | United States, Israel, United Kingdom | Seed, Pre-Seed | Blockchain, Biotechnology, Cryptocurrency | |
|
Ethan Oren Perlstein
Angel
|
4 | United States, Canada | Seed | Biotechnology, Cannabis, Biopharma | |
|
Darrin Disley
Angel
|
4 | United Kingdom | Seed, Series A | Biotechnology, Health Care, Big Data | |
|
Ling Wong
Angel
|
4 | United States, Colombia | Series A, Series B, Series C | Biotechnology, Health Care, Medical | |
|
Annie Vereecken
Angel
|
4 | Belgium | Seed, Series A | Biotechnology, Medical, Hospital | |
|
Penny Schiffer
Angel
|
4 | Switzerland, Germany, United Kingdom | Seed, Series A | Health Care, Medical, Finance | |
|
T. Chen Fong
Angel
|
4 | Canada, Singapore, United States | Seed, Angel, Pre-Seed | Software, Artificial Intelligence, Biotechnology | |
|
Daren Cotter
Angel
|
4 | United States | Seed, Series A | Software, E-Commerce, Information Technology | |
|
Bernard Majoie
Angel
|
4 | France, Belgium | Seed, Pre-Seed, Series A | Biotechnology, Medical, Health Care | |
| Access all 1886 angel investors in Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Series B
- Geography: United Kingdom, United States, Spain
Investor stats
- Total investments: 61
- Round size: Seed $537k–$16M; Series A $4.1M–$50M; Series B $1.6M–$56M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
- Constructive Bio — We place non-canonical amino acids at precise positions in proteins and peptides to create therapeutics with new properties, then manufacture them through fermentation.
- LIfT BioSciences — LIfT BioSciences is a socially-minded Biotech start-up that develops a portfolio of potentially life-saving immuno-oncology cell therapies for different solid tumors using its innate immunity platform. Its goal is to create a Cell Bank with the potential to cure cancer, using Leukocyte Infusion Therapy.LIfT BioSciences was founded in 2016 andheadquartered in London, England.
Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been thefirst investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 54
- Round size: Seed $150k–$6.7M; Pre-Seed $110k–$1.5M; Series A $13M–$55M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
- Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Jeff Dean is the Chief Scientist of Google DeepMind and Google Research. He joined Google in 1999 and has played a pivotal role in shaping the company’s technical foundations. He currently focuses on advancing AI and deep learning research across Google’s research teams.He co-founded and led the Google Brain team, helping drive innovations indeep learning for speech recognition, computer vision, natural language understanding, and a wide range of predictive applications. Over the years, he has co-designed and implemented several generations of Google's core systems, including its web search infrastructure, crawling and indexing pipelines, and advertising technologies such as AdSense for Content.He is also a key contributor to Google's distributed computing infrastructure, having co-designed and implemented systems like MapReduce, BigTable, Spanner, Protocol Buffers, LevelDB, and TensorFlow—one of the most widely used open-source machine learning platforms.Jeff Dean earned his Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the ACM-Infosys Foundation Award in the Computing Sciences and the Mark Weiser Award.
Show more...Investment focus
- Industry: Artificial Intelligence, Information Technology, Software
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Japan
Investor stats
- Total investments: 93
- Round size: Seed $2.5M–$35M; Pre-Seed $450k–$3M; Series A $6.1M–$53M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- Terraton — Terraton is a biochar platform that provides equipment, design, and financing to agribusiness operators.
- Moonlake AI — Vibe code games and worlds into existence.
- Periodic Labs — Periodic Labs develops artificial intelligence systems that simulate and predict the properties of materials using machine learning. The company applies computational models to support the discovery and design of materials used in sectors such as energy, electronics, and infrastructure. It builds tools that aim to reduce the time and costassociated with traditional research and development processes. Periodic Labs uses AI to analyze large-scale scientific data and collaborates with academic and industry partners to support material science research.
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 55
- Round size: Seed $1.4M–$4.7M; Angel $190k–$1.3M; Pre-Seed $1M–$2.8M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
- Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!
- Athens Research — Open-Source Roam Research. A private, extensible, and community-driven knowledge graph.
Paul Buchheit is based out of Mountain View, California and is the Co-Founder and General Partner of Standard Capital. Paul Buchheit attended Case Western Reserve University.
Show more...Investment focus
- Industry: Software, E-Commerce, Health Care
- Stage:Seed, Series A, Angel
- Geography: United States, Canada, India
Investor stats
- Total investments: 152
- Round size: Seed $1.1M–$5M; Angel $100k–$1.6M; Series A $2.5M–$13M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- SiPhox Health — Painless, 5-minute biomarker testing at home. Clear insights, trend tracking, and a personalized plan built around your results.
- BuildForever — BuildForever build products that feel personal, magical and deeply human.
- Perplexity — Perplexity is a search engine platform that uses artificial intelligence to provide large language models and search engines. The company's platform enables the development of beneficial artificial general intelligence, as well as an open-source environment that is accessible to the public, allowing clients to develop skills and knowledge inartificial intelligence.
Sahin Boydas is the PEF Chapter Lead of PEF Community. He previously worked at RemoteTeam.com as CEO and Founder. Sahin Boydas attended Koç University, where he took a Bachelor of Science in Computer Engineering, and Bahcesehir University, where he took a Master of Business Administration in Entrepreneurship.
Show more...Investment focus
- Industry: Software, Financial Services, Information Technology
- Stage:Seed, Series A, Series B
- Geography: United States, Mexico, Norway
Investor stats
- Total investments: 180
- Round size: Seed $125k–$34M; Series A $6M–$35M; Series B $23M–$150M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Seezo — Seezo provides security design reviews for every feature a company builds, leveraging Gen AI to scale threat modeling. The platform helps developers ship features faster by identifying potential risks and vulnerabilities. Seezo focuses on application security (AppSec) and aims to integrate security seamlessly into the development process.
- Neurable — Neurable develops software to understand human intent by using advanced machine learning techniques to classify the electrical signals produced by your brain. Neurable's software turns these biometric signals into actionable insights for measuring emotion and providing control of connected devices.
- Reliable Robotics — Advanced automation will make aircraft safer, more available, more affordable and fundamentally transformative to the way goods and people move around the planet.
Angel Investor located in Charlottesville, VA
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A, Angel
- Geography: United States
Investor stats
- Total investments: 47
- Round size: Seed $640k–$4.3M; Angel $250k–$2.6M; Series A $3.4M–$11M
- Lead/follow: 9% lead, 91% follow
Portfolio highlights
- Yogi — Yogi's analytics platform lets you easily sift through customer Reviews & Ratings data. Get actionable insights from your product Reviews, Ratings, and Sentiment Analysis to improve your brand reputation and product experiences.
- Knit — Knit helps researchers run agency-quality quant + qual research at DIY costs, by taking the most time-intensive research tasks off their plate through Researcher-Driven AI.
- Contraline — Contraline is a medical device company that has developed a proprietary injectable hydrogel platform for use in reproductive and contraceptive applications. Contraline's first product, Adam, is implanted into the vas deferens through a minimally invasive, outpatient procedure and once implanted, the gel effectively blocks sperm. Adam isnon-hormonal, designed to last years, and easily reversible.
Kingsley Advani (born October 24, 1993, in London, United Kingdom) is a British tech entrepreneur, investor, and author based in Dubai, United Arab Emirates. He is the Founder and CEO of Allo, an exchange for tokenized stocks managing over $2 billion in tokenized real-world assets, and the founder of Allocations, a fintech platform that has grownto administer more than $2 billion in assets across 30,000+ high-net-worth clients.Advani began his entrepreneurial journey at the age of 13, launching a digital commerce business on eBay, before discovering Bitcoin in 2011 while studying finance and economics. In 2013, he allocated his IBM internship savings into Bitcoin and other emerging cryptocurrencies, becoming an early investor in what later became a multi-billion-dollar asset class. By his mid-twenties, he had invested in more than 200 companies, including unicorns such as SpaceX, Solana, Coinbase, Robinhood, and eToro.In 2017, he co-founded a global investor syndicate that collectively managed more than $4 billion in assets. Two years later, he launched Allocations, a platform providing infrastructure for fund administration, SPVs, and private market investments. CNBC recognized him as the “Blockchain Oracle” for his early insights into cryptocurrency adoption and market trends.Through his ventures, Advani has become a leading voice in fintech, blockchain, tokenization, private markets, and Web3, with frequent speaking engagements at global conferences including the SF Blockchain Summit, Beyond Blocks, Coinfest Asia, and the Ritossa Summit in Dubai. His commentary emphasizes how blockchain and emerging technologies can democratize access to alternative assets and reduce the barriers to launching micro-funds.Advani is also the author of The Blockchain Oracle: How Technology, Finance, and Vision Shape the Future of Global Investing (2025), a book that explores the intersection of blockchain, fintech, and global finance.
Show more...Investment focus
- Industry: FinTech, Biotechnology, Financial Services
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, Singapore, United Kingdom
Investor stats
- Total investments: 45
- Round size: Seed $120k–$4.3M; Pre-Seed $120k–$4.5M; Series A $4M–$183M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Orbit Fab — Orbit Fab is creating the future of on-orbit satellite refueling. We maximize your operational assets by enabling mission flexibility and freedom of action in space.
- Juvenescence — We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases.
- Volumetric — Advanced materials and 3D biofabrication.
Farzad (Zod) Nazem has been a prolific angel investor and advisor to tech startup companies since his retirement from Yahoo! in 2007. He has invested in more than 60 early stage companies, and sits on the boards of Hand Foundation, and The Nueva School. His area of investment is about two thirds Big Data and Cloud platforms, and one third Healthand Medical. He was the Executive Vice President of Engineering and Chief Technology Officer of Yahoo from 1996 to mid 2007. He helped acquire and integrate over 50 companies and managed over six thousand engineers representing half of the company's employees. Between 1985 and 1996, Mr. Nazem held various software development and management positions at Oracle Corporation culminating in his role as Vice President of Media and Web Server Division. His tenure at Oracle also included membership in the company's Product Division Management Committee, which set overall strategy for Oracle products. Previously, Mr. Nazem was recruited from California Polytechnic State University by Rolm Corporation to be a software engineer in the VLCBX division. At age 19, he earned a B.S. degree in Computer Science with highest honors.
Show more...Investment focus
- Industry: Health Care, Software, Analytics
- Stage:Seed, Series A, Series B
- Geography: United States, Canada
Investor stats
- Total investments: 64
- Round size: Seed $750k–$6.5M; Series A $2.8M–$14M; Series B $6M–$50M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Emailage — Emailage is a developer of fraud prevention and identity verification technology used to make transactions easier and secure. The company provides multi-faceted predictive solutions with email at the core through key partnerships, proprietary data, and advanced machine-learning technology. It proprietary algorithms in order to provide real-timealerts of risky transactions and delivers a risk score and enable companies to realize significant savings from identifying and stopping fraudulent transactions and improve customer experience.
- Ceevra — Ceevra is an advanced 3D visualization technology for surgeons. Using AI and other innovative computing techniques, Ceevra generates brilliant 3D digital models from standard CT scans and MRIs. Surgeons use the Ceevra 3D models to help educate and counsel patients, to decide on the best surgical approach, and to gain important insights whileoperating.
- TigerGraph — TigerGraph is the leading AI-powered graph database. Uncover hidden relationships, run real-time analytics at scale, and power fraud detection, customer 360, and AI
blah - teh software was teh busted and they didn't want to fix it or hire someone to fix it, odd folks, these.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Robotics
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, India
Investor stats
- Total investments: 49
- Round size: Seed $2.3M–$9.1M; Pre-Seed $325k–$2M; Series A $10M–$57M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Sorare — Global Fantasy Football. Collect limited edition digital collectibles, Manage your team and earn prizes!
- MightyFly — MightyFly is enabling worldwide access to goods with fast, on-demand delivery services for businesses and consumers. We’re putting the infrastructure in place to connect remote locations together with long range, heavy cargo aircraft. Many areas in the world today suffer from an inability to obtain critical and often urgently needed goods andsupplies at an affordable cost. Our goal at MightyFly is to solve this problem through express, customized aerial drone delivery services. MightyFly drones will transport cargo to multiple locations in a single flight across hundreds of miles of remote terrain that is difficult if not impossible to cross with trucks or other ground vehicles. We are developing vertical-takeoff-and-landing (VTOL) drones that fly more than 300 miles, and carry payloads in excess of 50 pounds at a fraction of the cost of helicopters. Featuring automated cargo loading and unloading, and requiring no launch or recovery infrastructure, MightyFly drones will accommodate ad-hoc deliveries to undeveloped sites as well as servicing locations along established routes.
- Bear Flag Robotics — Safe, productive and efficient farming operations for the next generation of growers. Customize, Orchestrate, Automate,and Scale your fleet to your needs.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Jeff Hammerbacher - Partner & Co-Founder @ Techammer
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: United States, Germany
Investor stats
- Total investments: 33
- Round size: Seed $1M–$20M; Angel $330k–$330k; Series A $3M–$25M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Vectara — Trusted AI Agents, Zero Compromises
- Modal Labs — Modal develops machine learning software to help run code in the cloud. The software enables users to run or deploy machine learning models, massively parallel compute jobs, task queues, web apps, and more. It also writes the code to launch hundreds of custom containers and runs scripts in the cloud faster than on the local machine.
- Together AI — Together will enable researchers, developers & companies to leverage and improve artificial intelligence with an intuitive data, models & computation platform.
Sam Altman is the CEO and co-founder of OpenAI. He is a Partner of Apollo Projects. Altman was the president of Y Combinator. Sam attended Stanford University.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Internet
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Ghana
Investor stats
- Total investments: 178
- Round size: Seed $1.2M–$10M; Series A $6M–$70M; Series B $17M–$100M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- GALY — GALY biocrafts premium cocoa and cotton with quality, traceability, and scalable supply for modern brands.
- BRINC Drones — BRINC is a US company developing tech in the service of public safety. Known for Drone as First Responder, indoor tactical drones and more.
- NOYACK — NOYACK builds agentic AI technology for wealth management, starting with NOYACK.ai—the first AI agent for financial literacy - and Prophit.ai , the first opensource AI agent for portfolio optimizations of ALL asset classes. The fintech platform uses autonomous AI to deliver personalized financial guidance and construct tax-optimized portfolioscombining traditional accounts (IRAs, 401(k)s, HSAs) with private market investments in venture capital, fine art, and real estate for Millennials and Gen Z investors
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Health Care
- Stage:Series A, Seed
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 32
- Round size: Seed $536k–$20M; Series A $4.6M–$46M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- OncoSenX — OncoSenX is a developer of transient gene therapies designed for solid tumors. The company's therapy delivers plasmid DNA with a novel lipid nanoparticle that selectively kills cancerous cells based on their transcriptional activity, providing cancer patients, doctors and medical care professionals with a less invasive and more preciseintervention for this complex and devastating disease.
- Netwealth — Netwealth provides expert investment management and tailored wealth planning solutions, helping you confidently achieve your financial goals.
- Repair Biotechnologies — Repair Biotechnologies is a developer of clinical gene and protein therapies intended to focus on the reversal of age-associated thymic atrophy and consequent loss of immune function. The company's platform is committed to developing treatments for ageing and age-related diseases that address the root causes of these conditions, enabling humanbeings to improve their health span through targeting the causes of age-related diseases and ageing itself.
CEO and Co-founder at Verge Genomics; Angel Investor in Tech-Enabled Bio
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom
Investor stats
- Total investments: 15
- Round size: Seed $120k–$5.9M; Series A $12M–$30M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Encellin — Encellin develops a novel thin-film cell encapsulation device for cell-based therapeutics. It has dedicated experts focused on the investigation and advancement of next-generation therapies. It aims to help patients with chronic diseases, starting with Type 1 diabetes. It was founded in 2016 and is headquartered in San Francisco, California.
- Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
- Arpeggio Bio — We engineer medicine based not on a single target, but the biological network as a whole.
Balaji S. Srinivasan is the Co-Founder and Board Member of Coin Center. He was the CTO of Coinbase and cofounder of Counsyl, Earn, Teleport, and Coin Center. Dr. Srinivasan holds a BS, MS, and PhD in Electrical Engineering and an MS in Chemical Engineering from Stanford University. He also teaches the occasional class at Stanford, including anonline MOOC.
Show more...Investment focus
- Industry: Blockchain, Cryptocurrency, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, India, Singapore
Investor stats
- Total investments: 242
- Round size: Seed $2.3M–$15M; Pre-Seed $665k–$4.2M; Series A $6M–$31M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Trepa —
- Parallax — Parallax offers a cross-border payments platform for freelancers, remote workers, and businesses. The service enables receiving international client payments, holding funds in USD, exchanging currencies, and sending money to domestic bank accounts and mobile wallets. Users manage balances and transfers through a web app with quoted rates anditemized fees. The platform supports global payouts and recurring disbursements to partners and team members. Compliance measures include identity verification and transaction monitoring aligned with regulatory standards. Documentation and support resources guide account setup, funding, and cash-out.
- Blueprint Bryan Johnson — On the surface, Blueprint may seem something about health, wellness and aging. It's really a system to make tomorrow better for you, me, the planet and our shared future with AI.
Wei Guo, the founding partner of UpHonest Capital, is an active angel investor in Silicon Valley, focusing on early-stage cross-sector investments. He founded Wei Fund in 2015 and UpHonest Capital Fund I in 2016, invested in well-known companies such as Hims&Hers(NYSE: HIMS), Vicarious Surgical(NYSE: RBOT), Knightscope (NASDAQ: KSCP), Checkr,Lime, Boom, Rescale, Dialpad and more. Since 2015, he has invested in over 400 Silicon Valley startups, over 76 companies with valuations greater than 100 million USD, and 23 portfolio companies that have successfully exited.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Angel
- Geography: United States, China, Canada
Investor stats
- Total investments: 154
- Round size: Seed $200k–$4.3M; Angel $375k–$10M; Series A $7M–$19M
- Lead/follow: 2% lead, 98% follow
Portfolio highlights
- tbh — tbh is a developer of a mobile application designed to provide anonymous feedback to friends. The company's mobile application facilitates asking or answering questions, open text fields and invite abuse when combined with anonymity, enabling users to say things without repercussions and feel better about themselves from the positive feedbackon social networks.
- Bungalow — Bungalow is a residential real estate platform that provides renters with a more convenient, flexible, and communal living solution. It utilizes existing housing supply by signing long-term leases with homeowners, and offers multi-bedroom homes in some of the most desirable neighborhoods in cities throughout the United States.Bungalow offersprivate bedrooms with handpicked housemates in beautifully furnished homes across seven major cities. Each home comes furnished and includes wifi, utilities, housekeeping, and monthly community events for members.Andrew Collins and Justin McCarty founded Bungalow in 2016. Its headquarters is in San Francisco in California.
- Raydiant — Raydiant empowers brick-and-mortar organizations to deliver engaging, personalized, and measurable on-screen digital experiences to delight in-store customers and engage back-of-house employees.
Chris Gibson is the Co-Founder and CEO of Recursion (Recursion Pharmaceuticals). He previously worked at Cure HHT as a Member Board of Directors. Chris Gibson attended the University of Utah.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Seed
- Geography: United States, France, Switzerland
Investor stats
- Total investments: 10
- Round size: Seed $4.9M–$14M; Series A $6.3M–$55M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Inato — Inato matches the right sites to the right clinical research study, globally.
- Known Medicine — Known Medicine is looking to take the experimentation of how tumors respond to cancer drugs out of the patient’s body and into the lab. The startup breaks down tumor samples into micro tumors, which they treat separately inside specialized micro-environments with different methods and see what works best.
- Leash Biosciences — We're transforming drug design with a rich dataset built by screening millions of compounds against thousands of protein to generate billions of data points, ideal for training advanced machine learning models.
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more...Investment focus
- Industry: Software, Biotechnology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: Italy, United Kingdom, France
Investor stats
- Total investments: 17
- Round size: Seed $100k–$45M; Pre-Seed $1.4M–$2.2M
- Lead/follow: 6% lead, 94% follow
Portfolio highlights
- iubenda — Make your sites & apps legally compliant across multiple languages and legislations (including the GDPR) with our lawyer-crafted, self-updating solutions.
- Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
- Golden — Golden is a developer of a self-constructing knowledge database used to accelerate discovery and education. The company uses and leverages human effort by using machine intelligence to make the process of gathering and communicating knowledge simpler.It combines a powerful search across several entities with fine-grain alerts to stay on top ofchanges, and semi-automatic research assistance for gaps in knowledge that enable people in organizations to stay current, understand and leverage the latest trends in their industry.
Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 114
- Round size: Seed $150k–$18M; Series A $5.8M–$36M; Series B $19M–$120M
- Lead/follow: 1% lead, 99% follow
Portfolio highlights
- Key AI — Unlock new networking and career opportunities with Key, the leading AI-powered professional networking platform. Build and manage communities, host and join exclusive events, and create meaningful connections to supercharge your growth all in one place.
- OrgOrg — OrgOrg provides internal SaaS tools for organizational productivity suite for the companies
- Odyssey — Odyssey operates as an AI start-up, provides hollywood-grade visual AI.
Evan Cheng Co-founder & CEO at Mysten Labs. He attended Syracuse University.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Australia
Investor stats
- Total investments: 27
- Round size: Seed $120k–$5.8M; Pre-Seed $150k–$10M; Series A $3M–$18M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Jarsy — Jarsy Inc offers a platform for global investment opportunities using stablecoins.
- Kontigo — We help underbanked gig workers in Latam build credit and access group financing where small groups of family or friends lend and save money together. Users can validate their income from multiple sources such as gig apps, catalog sales, and open finance (Uber, Rappi, Didi, Indriver, Avon, and all major banks). After verifying the income wedirectly offer them group savings and group loans, without leaving WhatsApp, their primary messaging app.
- Kite AI — Kite AI is a purpose-built, EVM-compatible L1 designed to power the AI economy.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Software
- Stage:Seed, Pre-Seed, Series A
- Geography: United Kingdom, France, Israel
Investor stats
- Total investments: 15
- Round size: Seed $850k–$3.1M; Pre-Seed $2M–$2M; Series A $18M–$19M
- Lead/follow: 7% lead, 93% follow
Portfolio highlights
- Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
- thymia — We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient.
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Tim Draper is the Founding Partner of Draper Associates. He attended Harvard Business School.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 283
- Round size: Seed $400k–$5.9M; Series A $2.5M–$25M; Series B $3M–$50M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- GALY — GALY biocrafts premium cocoa and cotton with quality, traceability, and scalable supply for modern brands.
- Buupass — BuuPass is Kenya's market leader for online bus booking. We enable travelers to reserve seats and make payments in a convenient and timely way. Try BuuPass today!
- Vivoo — Get personalized wellness insights with Vivoo's innovative, science-backed products. Understand your body's needs and take control of your body. Shop now!
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 179
- Round size: Seed $1.1M–$8M; Pre-Seed $510k–$5.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skrap — Skrap is an on-demand mobile marketplace for skip hire and other waste collection services.
- BirdyChat — BirdyChat is a Developer of a work chat application intended for work professionals.
- Hyphen SCS — Find and rent verified warehouses across 992+ cities in India. Compare 65,000+ listings on Hyphen SCS.
Before co-founding Flatiron, Zach was Co-Founder, President and COO of Invite Media, an advertising technology company based in NYC. Invite Media built the industry's first enterprise advertising platform for buying and optimizing online media in real-time. Invite Media was acquired by Google in 2010. Prior to Invite Media, Zach co-foundedEatNow.com which was privately acquired. An active angel investor, Zach has invested in over 30 technology startups throughout the country, including Bell Biosystems, Breakthrough.com, Care at Hand, DocPhin, Doctor Evidence, Genomera, Meddik, Oscar, and Predilytics. Zach studied economics and entrepreneurship at The Wharton School at the University of Pennsylvania.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 67
- Round size: Seed $1.4M–$6.3M; Pre-Seed $1.5M–$2.3M; Series A $3M–$30M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Iterative Scopes — Iterative Scopes provides gastroenterologists with machine learning-powered diagnostic tools that help them prevent colon cancer and improve patient outcomes
- Overwatch Research — Generate accurate in vivo study data as a part of your efficient, connected R&D.
- Nym — Nym Health leverages advanced AI for medical coding, revolutionizing accuracy and speed within revenue cycle management. Discover the difference.
Cory Levy is the Founder of Z Fellows. He previously worked at DoSomething.org as a Board Member. Cory attended University of Illinois Urbana-Champaign, where he took Computer Science.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Advertising
- Stage:Pre-Seed, Seed, Series A
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 70
- Round size: Seed $1.6M–$15M; Pre-Seed $200k–$3.3M; Series A $14M–$72M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- Wander — Never book a bad vacation home again. Every Wander comes with hotel-grade amenities, inspiring views, pristine cleaning and 24/7 concierge service.
- Pilgrim — Pioneering a biologically enhanced future for humanity.
- Swish Robotics — Embodied Intelligence for the Home
Brian Armstrong is the CEO and Co-Founder of Coinbase. He previously worked at Airbnb.com as a Technical Product Manager. Brian Armstrong attended Rice University.
Show more...Investment focus
- Industry: Biotechnology, Payments, Financial Services
- Stage:Seed, Series A, Series B
- Geography: United States, Brazil, Libya
Investor stats
- Total investments: 18
- Round size: Seed $2M–$12M; Series A $13M–$30M; Series B $45M–$130M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Brain Co. — AI platform and applications for the world's most important institutions
- NewLimit — NewLimit is extending human healthspan by unlocking regenerative potential.
- Preventive — Preventive mission is to determine whether the newest generation of gene editing technologies can be used safely and responsibly to correct devastating genetic conditions for future children.
John Ballantyne is a founder of Agathos Biologics. He co-founded Aldevron with Michael Chambers in 1998 and has been the Chief Scientific Officer since its establishment. His innovative work at Aldevron includes creation of the GMP Source product line and collaborative research with military scientists in the development of vaccine andpassive-based countermeasures to lethal and potentially weaponized viral hemorrhagic threats such as Ebola, Marburg and some hantavirus family members. He leads the research and development team at Aldevron which develops new methods and products through internal programs, collaborations, and technology licensing. John sees the advances in biotechnology providing opportunities for Agathos to enable ethical pharmaceutical development that will benefit patients, employees, and society. Ballantyne received undergraduate degrees in Pharmacy from the Central Institute of Technology and the University of Otago in New Zealand. After beginning graduate school in New Zealand he transferred to the United States in 1994 and completed his Ph.D. in Pharmaceutical Sciences at North Dakota State University.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Seed, Series A, Angel
- Geography: United States
Investor stats
- Total investments: 11
- Round size: Series A $12M–$30M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- VerImmune — Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirectspre-existing pathogenic or childhood vaccine immune memory towards tumors.
- SmartWorx — SmartWorx is an AI-native, no-code enterprise platform that redefines how organizations build, integrate, and scale business applications. Powered by a metadata-driven architecture, SmartWorx leverages multi-agent AI to dynamically build applications, configure the platform itself, or be applied directly to an organization’s own data. The result isa unified environment that replaces fragmented ERP, CRM, and ITSM systems with extensible, real-time solutions supported by a marketplace of pre-built apps and integrations. Designed for both commercial and government use, SmartWorx enables rapid innovation, interoperability, and compliance at scale—empowering enterprises to transform how software is created and adapted.
- GlucoTrack —
Fred Ehrsam is the Co-Founder of Paradigm.
Show more...Investment focus
- Industry: Blockchain, Cryptocurrency, Software
- Stage:Seed, Series A, Series C
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 54
- Round size: Seed $1M–$12M; Series A $7M–$45M; Series C $65M–$300M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- NewLimit — NewLimit is extending human healthspan by unlocking regenerative potential.
- Wispr Flow — Wispr AI is a developer of the next-generation of neural interfaces to provide seamless interface with immersive technology. The company is working with the leading neuroscientist, hardware engineers, machine learning researchers, and product engineers to bring frontier technology to the mass consumer market.
- Socket — Socket fights vulnerabilities and provides visibility, defense-in-depth, and proactive supply chain protection for JavaScript, Python, and Go dependencies.
Mark Cuban is the founder of Fireside, Chairman and Founding Partner of AXS TV, and the Owner of Dallas Mavericks. He previously worked at Broadcast.com as a Co-Founder. Mark Cuban attended the Indiana University Bloomington.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Blockchain
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 186
- Round size: Seed $600k–$9M; Series A $3.2M–$23M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- ethpass — Unlock real-world experiences by connecting your digital assets to Apple and Google Wallet
- AlchemyNFT — AlchemyNFT is a non-fungible token (NFT) service.
- Injective — Explore Injective: the high-performance blockchain powering decentralized finance, governance, and next-gen Web3 apps with unmatched speed and scale.
Mei is an early stage investor focused on AI. Mei studied at MIT and the MIT Media Lab
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: United States, United Kingdom, Singapore
Investor stats
- Total investments: 31
- Round size: Seed $4M–$300M; Pre-Seed $1M–$11M; Series A $17M–$155M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Coframe — Transform your website with AI-driven optimization and personalization that boosts engagement and conversions. Coframe automates growth 24/7.
- Harmonyze — Harmonyze transforms fragmented franchise operations data into clear, daily, revenue-boosting recommendations with AI-powered coaching.
- Black Forest Labs — Black Forest Labs creates advanced generative deep learning models for images and videos. They focus on making these technologies widely accessible and transparent, ensuring that their innovations are easy to use and understand. This approach aims to democratize access to cutting-edge technology and foster greater trust and utility.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Elad Gil is the Co-Founder of Color Genomics. He previously worked at Twitter as a Vice President. Elad Gil attended the Massachusetts Institute of Technology.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Israel
Investor stats
- Total investments: 239
- Round size: Seed $2M–$15M; Series A $9.5M–$50M; Series B $28M–$100M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- Petual — Petual is building the AI-powered platform for audit and compliance, transforming how enterprises manage SOX, operational, financial, and compliance risk. Our intelligent agents deliver precision, coverage, and speed impossible with manual testing.
- Harvey — Harvey is an artificial intelligence technology service provider.
- BuildForever — BuildForever build products that feel personal, magical and deeply human.
Sake Bosch is a Founder and Managing Partner of Prime Ventures since 1999. Sake brings over 25 years of experience in marketing and sales and venture capital to Prime. Prior to founding Prime in 1999, Sake was a Senior Principal at Holland Venture and was responsible for managing investments in technology companies. Sake was involved in many ofthe Holland Venture technology investments including Applicare Medical Imaging (acquired by GE Medical Systems), BWise (acquired by Nasdaq), SQL Systems (acquired by Datastream) and Freecom (acquired by Mitsubishi Kagaku Media). Before joining Holland Venture in 1994, Sake worked as an Independent Corporate Finance Consultant focusing primarily on early stage companies. Prior to this position Sake was a Sales Executive at Securitas Group. Sake started his career in 1989 as a Strategic Market Analyst at VNU. Sake serves on the board of directors of Civolution, 4C, Dealerdirect, Digital Origin, Greetz, Forcare, SaaSPlaza, SlimPay and Takeaway.com. Previous investments include: 3mensio Medical Imaging (acquired by Esaoto), eBuddy (acquired by Booking.com), Global Collect (acquired by General Atlantic), MarketXS (acquired by Markit), Nedstat (acquired by comScore Inc.), Tridion (acquired by SDL) and Watermark (acquired by Qurius). Sake holds an M.Sc. degree in Business Administration as well as a B.A. degree in Management Science and Industrial Engineering.
Show more...Investment focus
- Industry: Software, E-Commerce, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: The Netherlands, France, Israel
Investor stats
- Total investments: 32
- Round size: Seed $1.9M–$9.5M; Series A $6.9M–$29M; Series B $7.1M–$77M
- Lead/follow: 41% lead, 59% follow
Portfolio highlights
- LionVolt — LionVolt is a battery startup company that claims to develop the most efficient solid state lithium-ion battery.
- Fairbrics — Fairbrics is developing the first synthetic fiber with a net positive impact on climate change and capable of meeting the demand of the market.
- Genomines — World resources are expected to be depleted in the next 30 to 50 years and increasing scarcity is driving metal prices up, sometimes doubling in a few years. 86% of ore that is being extracted, containing up to 10years+ metal consumption, is not processed as metal concentration is too low. Each year a volume of low-metal concentrated soilsequivalent to the area of Paris and 100m high is extracted and not processed. It is not only a missed opportunity to recover significant amounts of metal, but it is also a serious risk for the environment. At Genomines, we bring together 2 worlds: Agriculture and Mining. We offer a sustainable alternative to conventional mining by genetically enhancing the natural ability of plants to hyperaccumulate metals.
Peter Thiel Is the Managing Partner of The Founders Fund. He previously worked at Stanford Law School as a Visitor. Peter Thiel attended Stanford University.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Series A, Seed, Series B
- Geography: United States, Germany, Canada
Investor stats
- Total investments: 215
- Round size: Seed $900k–$8.5M; Series A $3M–$32M; Series B $16M–$105M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Hebbia — Hebbia's neural search lets you execute research 10X faster and 10X more accurately. Transform your productivity today.
- Mercor — Find top-tier, remote, AI roles for your expertise. Available only on Mercor.
- Reserve — Reserve is a universal currency company. Reserve provides people with hyperinflation protected savings accounts to protect and use their money globally. They offer rtokens, collateral baskets, and over collateralization.
Kevin Moore has 10 years experience as an angel/opportunity investor and operator. Prior to that, he has over 15 years of progressive technology i-banking, corp dev, and CFO experience at startups and $Bn corporates.
Show more...Investment focus
- Industry: Software, Health Care, E-Commerce
- Stage:Seed, Pre-Seed, Angel
- Geography: United States, India, Canada
Investor stats
- Total investments: 99
- Round size: Seed $190k–$5.2M; Pre-Seed $120k–$3.6M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- VantedgeAI — Fine-tuned AI models for scaling credit investing workflows, reducing analysis time and costs by up to 10x, and setting a new standard in rapid, cost-effective deal analysis and monitoring with initial focus on MBS, ABS, CLOs, etc.
- Binarly — Binarly is the world's most advanced automated firmware supply chain security platform. Using cutting-edge machine-learning techniques, Binary identifies both known and unknown vulnerabilities, misconfigurations, and malicious code in firmware and hardware components.
- SilkChart — SilkChart helps growth teams improve campaigns based on what users are doing in product - without relying on expensive data scientists. We do this through a no code analytics tool that combines marketing and product usage data to identify which channels, audiences, and content maximize revenue growth.
Anne Wojcicki is the Co-Founder and CEO of 23andMe. She previously worked at Passport Capital as a Healthcare Analyst. Anne Wojcicki attended Yale University.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 60
- Round size: Seed $1M–$12M; Series A $7M–$70M; Series B $17M–$60M
- Lead/follow: 2% lead, 98% follow
Portfolio highlights
- World Labs — World Labs is an AI startup that can analyze visual data with comprehension akin to a person's, a substantial advancement above existing capacities.
- The Invention Network — ScaleIP is an IP business intelligence platform that helps companies monetize IP.
- Solace — Connect with expert patient advocates who can help you navigate the healthcare system and solve any medical problem, no matter what you need.
Jan Hammer is the partner at Index and the Board observer of Harmonic. Jan attended Oxford University.
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States, France
Investor stats
- Total investments: 72
- Round size: Seed $2.5M–$15M; Series A $2.8M–$50M; Series B $14M–$250M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Sofía — Improving the way millions of people take care of their health
- Transak — Transak offers a simple integration to allow your users to buy more than 100+ cryptocurrencies with credit/debit cards, or bank transfers in more than 120+ countries.
- Yuetong Eye Clinic — Yuetong Eye Clinic is a medical institution that provides myopia surgery for adults and myopia prevention and control for adolescents. It is a medical institution focusing on adult myopia surgery and adolescent myopia prevention and control.
Alec Nielsen is the Founder & CEO at Asimov.
Show more...Investment focus
- Industry: Biotechnology, Biopharma, Medical
- Stage:Seed, Pre-Seed
- Geography: United States, Germany
Investor stats
- Total investments: 6
- Round size: Seed $3M–$16M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Trilobio — Biology is the future, but most lab technology is stuck in the past. Trilobio is rebuilding the biology lab from the ground up to unlock its true potential.
- Cache — Biomolecules are the next bits of the 21st century. So we're developing the first wet operating system for storing, accessing, and computing biomolecules at scale to make them widely accessible and useful. We're enabling the storage and access to the whole data universe—digital and biological—forever so that we don't have to deleteor dispose of anything ever again.
- General Proximity — General Proximity is a pioneering future-oriented proximity medicine that envisions the future of medicine.
Erik Peterson is the Founder at DormTrader.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Seed, Equity Crowdfunding, Series A
- Geography: United States, Canada, Algeria
Investor stats
- Total investments: 60
- Round size: Seed $150k–$4.5M; Series A $4M–$20M; Equity Crowdfunding $69k–$4.9M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Hideout — Hideout makes high-quality food that is available for delivery. Danielle Sobel established the company in Los Angeles, California.
- Abalone Bio — Our Functional Antibody Selection Technology platform (FAST) taps into the potential of the body's biological activities, expanding the reach of antibody drugs.
- Altay Therapeutics — Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
Daniel Curran is the Founder and CEO at CustEx.com.
Show more...Investment focus
- Industry: E-Commerce, Software, Internet
- Stage:Seed, Series A, Series B
- Geography: United States, Canada, Brazil
Investor stats
- Total investments: 145
- Round size: Seed $600k–$5M; Series A $3.6M–$23M; Series B $2.3M–$50M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- RentoMojo — RentoMojo is an online furniture rental platform that was incorporated in November 2014.It currently operates in Bangalore, Pune, Mumbai, Hyderabad, Chennai, Delhi, Gurgaon and Noida.RentoMojo was founded by Geetansh Bamania, an ex-IITM, in November 2014 in India. Like many other young working professionals, he was living in rented apartments,working long hours and found it inconvenient to equip the house with furniture when he moved. RentoMojo was developed to provide an alternative to buying and selling furniture in rental properties.
- Shred Video — Shred Video, a new startup launching out of Y Combinator, allows users to take footage from their iPhone, GoPro or drone and simply match it with a song from the user’s iTunes library. That’s all. Shred Video does the rest of the work.Taking into account the acceleration of the camera itself, Shred Video can pin-point the moments of action forsurfers, snowboarders, skaters and other acceleration-based sports to highlight all of the coolest clips in your footage. And beyond that, Shred Video matches those epic moments with the beat-drop of the song.
- GC Plus — Find Your Next Home Service Expert With Ease
Bhavik Bajaj
Show more...Investment focus
- Industry: Information Technology, Software, FinTech
- Stage:Pre-Seed, Seed, Angel
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 74
- Round size: Seed $100k–$3M; Angel $15k–$1.6M; Pre-Seed $43k–$1.3M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Asepha — Asepha is an AI clinical decision support (CDS) tool to help healthcare professionals make faster clinical decisions.
- ORA Technologies — E-Commerce, Super App
- THIRUMALS PAPER ARIZONA PVT. LTD. — TRADING PLATFORM OF PULP , PAPER & PACKAGING
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Candan Karabagli - Yönetim Kurulu Başkanı, CHAIRMAN @ GS Yuasa
Show more...Investment focus
- Industry: Retail, Analytics, Biopharma
- Stage:Seed, Angel, Series A
- Geography: Turkey
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- Biolive — Biolive
- Vispera — Drive your retail execution to perfection with Vispera image recognition technologies and intelligent retail solutions.
- PhiTech Bioinformatics — PhiTech pioneers the integration of DNA & RNA sequencing data with AI for rare disease diagnostics. We offer the first RNA-based diagnostic support tool.
Benjamin Kong is a Canadian investor backing early-stage transformative startups in Space, Biotech, Life Sciences, AI, Longevity, and Blockchain. He started investing in 2014 and has since funded over 50 startups and 3 VC funds. Recent early stage investments include Luminous Computing, Orbit Fab, Relativity Space, Swarm, TransAstra, RadianAerospace, Volumetric, OISIN, OncoSenX, Aegis BioDefense, Excision Biotherapeutics, MAIA Biotechnology, Ashvattha Therapeutics, ZenGo, Coinbase, Algorand, Oasis Labs, Arweave.
Show more...Investment focus
- Industry: Blockchain, Biotechnology, Cryptocurrency
- Stage:Seed, Pre-Seed
- Geography: United States, Israel, United Kingdom
Investor stats
- Total investments: 13
- Lead/follow: no public data
Portfolio highlights
- Radian — Radian Aerospace (Radian) is disrupting the aerospace industry with a next generation aerospace vehicle that is the world’s first fully reusable horizontal takeoff and landing, single-stage to orbit spaceplane, delivering people and light cargo to low earth orbit (LEO) and multiple terrestrial destinations with aircraft-like operations.
- Volumetric — Advanced materials and 3D biofabrication.
- Excision BioTherapeutics — Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Over the course of the last decade, first as a graduate student at Harvard University in the Department of Molecular and Cell Biology with PhD advisor Professor Stuart Schreiber and then as an independent postdoctoral fellow at the Lewis-Sigler Institute at Princeton University, Dr. Ethan Perlstein developed an approach to studying old drugs anddiscovering new drugs in model organisms called evolutionary pharmacology. Ethan is an author on 19 peer-reviewed scholarly publications, including the discovery of a novel mechanism of action for the antidepressant Zoloft based on studies in yeast cells.
Show more...Investment focus
- Industry: Biotechnology, Cannabis, Biopharma
- Stage:Seed
- Geography: United States, Canada
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- Epinoma — Epinoma is a diagnostics company that focuses on the multi-omics approach to cancer monitoring. It engineers proteins that control the operating system of biology. The company was founded in 2020 and is headquartered in San Francisco, California.
- BluumBio — BluumBio develops next-generation remediation technologies that clean up pollution and restore degraded ecosystems
- Promakhos Therapeutics — A Boston-based biotech startup developing therapeutics.
Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Big Data
- Stage:Seed, Series A
- Geography: United Kingdom
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Dr. Ling Wong is Founder and General Partner of Highbury Group and Sea Lane Ventures. She also serves as Senior Advisor to Lightspeed Venture Partners. Highbury Group was founded on the principle to be a true partner and champion to entrepreneurs, using science and technology to build companies that fundamentally transform the world for thebetterment of humanity today, and in the future.Dr. Wong draws from her unique background and experience as a scientist, entrepreneur, and investor to support and bring to market companies that exist at the intersection between health and technology. “I love to partner with mission-oriented founders working on transformational ideas that can have a positive, lasting impact on society – and do so by leveraging technology and science in a financially sustainable manner,” said Dr. Wong.Prior to Highbury, she served at the Gates Foundation where she helped to establish a $1.5B global investment portfolio and created a $200M early stage program to support early stage entrepreneurs in more than 60 countries.As a health and technology investor, Dr. Wong has been involved in some of the market’s most significant investments and exits. She has partnered with over fifteen $1B+ companies, including: Devoted Health, Orca Bio, Collective Health, Color, Apeel, Shape, Stripe, Offer Up, Rappi, Branch Metrics, Notion, Modern Animal, Wheel and Satellite Bio. Notable exits include: Anacor Pharmaceuticals (acquired by Pfizer for $5.2B), Genocea Biosciences (NASDAQ: GNCA), Visterra (acquired for $430M), Slack (NYSE: WORK), Guardant Health (NASDAQ: GH), and recently Singular Genomics (NASDAQ: OMIC).Dr. Wong holds a PhD from Harvard in Engineering Sciences, a BSc in Chemical Engineering and BSc in Biology from MIT. During her time at Harvard, she created the world’s first inhaled TB vaccine. Her scientific training has shaped how she assesses financial opportunities, both to create value and to benefit human health. Dr. Wong has always been passionate about seeking entrepreneurs and partners that are looking to disrupt the status quo in science and technology for the betterment of society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Colombia
Investor stats
- Total investments: 27
- Lead/follow: no public data
Portfolio highlights
- Satellite Bio — Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.
- Devoted Health — Devoted Health is a new healthcare company serving seniors. Aiming to launch Medicare Advantage plans in 2019, their mission is to build a healthcare solution good enough for Mom. They will be devoted to the health and wellness of their members by helping them navigate the health care system with personal guides, by utilizing world-class technologyto enable a simplified experience, and by partnering with top providers for better health outcomes.
- Shape Therapeutics — Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA Gene Therapy, potentially enabling the development of cures in neurodegenerative, metabolic and rare genetic diseases through our breakthrough payload, delivery, and manufacturing platform technologies. Our vision is to facilitate adoption of thesetechnologies throughout the industry to develop effective treatments for as many patients as possible.
Annie Vereecken
Show more...Investment focus
- Industry: Biotechnology, Medical, Hospital
- Stage:Seed, Series A
- Geography: Belgium
Investor stats
- Total investments: 6
- Lead/follow: no public data
Portfolio highlights
- Ziphius — Ziphius Vaccines is a biopharmaceutical company dedicated to developing next-generation vaccines for the prevention of infectious diseases.
- Sensolus — Introducing our smart, industrial-grade tracking solution. With battery life of up to ten years, and no additional infrastructure needed.
- Allegro Biotech — Allegro has developed the world’s-first custom-tailored, durable, biocompatible, anisotropic, regenerative meniscus cartilage, providing immediate support while also leverage the body’s own healing potential to regenerate human cartilage (proliferation and differentiation of fibrochondrocyte cells).
Penny Schiffer - CEO & Co-founder @ Raized.ai
Show more...Investment focus
- Industry: Health Care, Medical, Finance
- Stage:Seed, Series A
- Geography: Switzerland, Germany, United Kingdom
Investor stats
- Total investments: 34
- Lead/follow: no public data
Portfolio highlights
- Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
- Enterprise Bot — Cost-effective Conversational AI solutions transforming customer interaction for global enterprises. Discover cutting-edge chat, email, and voice tech.
- Scientific Visual — Scientific Visual supplies quality control workstations to visualize defects in non-polished sapphire such as watch covers, ingots and wafers.
Dr. Fong is a Professor Emeritus at the Faculty of Medicine, University of Calgary. He was formerly the Head of the Department of Radiology at the University of Calgary and the Calgary Health Region. Dr. Fong is active in funding and nurturing start-up companies. Over the past two decades, he funded over 50 companies in diverse technology sectors,with an emphasis in medical devices. Dr. Fong is the co-founder and board member of Calgary Scientific Inc. and is also on the board of Clarius Mobile Health, Cohesic Inc. and Innovere Medical. In addition to seed investing, Dr. Fong is active in the Calgary community sitting on six charitable boards and foundations.In 2015, Dr. Fong joined the Creative Destruction Lab (CDL) at the University of Toronto business school as a mentor. CDL helps young entrepreneurs to shape or pivot their nascent ideas. He is widely credited with launching CDL at the Haskayne School of Business at the University of Calgary, bringing together seasoned business leaders from Alberta, Canada and the US to grow budding companies. Dr. Fong is on the Strategic Advisory Board of CDL and a Fellow of CDL in Toronto, Montreal, Calgary and Vancouver. In 2017, Dr. Fong was named to the Order of Canada for his contribution to medical technology innovation and philanthropy.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Biotechnology
- Stage:Seed, Angel, Pre-Seed
- Geography: Canada, Singapore, United States
Investor stats
- Total investments: 12
- Lead/follow: no public data
Portfolio highlights
- Oncoustics AI — Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.
- SunGreenH2 — SunGreenH2 creates the world's highest performance advanced materials for electrolysis i.e. green hydrogen production. Achieve high efficiency, low cost green H2 production on site for your application in the Power-to-X, Hydrogen refuelling, Energy Storage and Buildings sectors. Revolutionising zero emissions and improving profitability.
- EZee Assist — EZee Assist provides instant answers to franchisee operational questions. Continue using preferred channels of support and start receiving instant answers.
Daren was the Founder and CEO of InboxDollars, an online marketing company that connects consumers and advertisers in a way that benefits both. He founded the company as a Freshman in college in 2000 and bootstrapped the company to more than $25 million in annual revenues. InboxDollars was acquired by Prodege in 2019. Daren is active in the MNstart-up community as an investor, advisor and mentor.
Show more...Investment focus
- Industry: Software, E-Commerce, Information Technology
- Stage:Seed, Series A
- Geography: United States
Investor stats
- Total investments: 79
- Lead/follow: no public data
Portfolio highlights
- Bonsai — Bonsai is the first-party marketing intelligence platform that automates profitable growth. Trust your marketing data, make confident decisions, drive revenue.
- Franzy — Franzy is the "Zillow for franchising"—a smarter, more transparent way to find, compare, and finance franchise opportunities. We match aspiring entrepreneurs with the right franchise brands based on their goals, experience, and budget, making the path to business ownership simpler, faster, and more accessible.
- Bonsai Data Solutions — Bonsai is the first-party marketing intelligence platform that automates profitable growth. Trust your marketing data, make confident decisions, drive revenue.
Bernard Majoie - President @ Fournier-Majoie
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Pre-Seed, Series A
- Geography: France, Belgium
Investor stats
- Total investments: 5
- Lead/follow: no public data
Portfolio highlights
- reMYND — Driving the development of disease-modifying treatments
- AgenT — AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms.
- PEP-Therapy — PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology
Biotechnology Angel investor funding at a glance
Stats across 1.7k deals from 1.9k investors.
Access all 1886 angel investors in Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Angel Investors investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 1886 angel investors investing in Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!